Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade

This article was originally published in The Pink Sheet Daily

Executive Summary

Policy changes since FDA's first biosimilar approval produce a label that is more clearly different than, but also more closely tied to, its brand reference.

Advertisement

Related Content

US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
Evolving Biosimilar Pathway Brings Mid-Review Policy Issues

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel